-5%
Decomit Inhaler is indicated for the preventive management of asthma in adults and children, including mild, moderate, and severe cases. It contains beclometasone dipropionate, an inhaled corticosteroid that reduces inflammation in the lungs. Compared to systemic corticosteroids, inhaled beclometasone offers effective anti-inflammatory action with fewer and less severe side effects.
Mild asthma: For patients who require regular use of a symptomatic bronchodilator.
Moderate asthma: For patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone.
Severe asthma: For patients with chronic severe asthma, including those dependent on systemic corticosteroids. Switching to high-dose inhaled beclometasone may allow a reduction or elimination of oral corticosteroid use.
Beclometasone dipropionate works by producing anti-inflammatory and vasoconstrictive effects in the lungs. While the exact mechanism of its anti-inflammatory action is not fully understood, corticosteroids are known to influence a wide range of cells and mediators involved in inflammation, including:
Cells: mast cells, eosinophils, neutrophils, macrophages, lymphocytes
Mediators: histamine, eicosanoids, leukotrienes, cytokines
Beclometasone dipropionate is a pro-drug with low glucocorticoid receptor binding. It is metabolized by esterase enzymes into its active form, beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory effects. Clinical studies showed no histopathologic changes in the nasal mucosa after intranasal administration.